Dame Siobhain McDonagh

Together with a number of Members here, I met representatives of Servier, and people are now in receipt of vorasidenib. I would be happy to talk to the hon. Lady about how we went about that. On its own, foundational research is not enough for the people who will be diagnosed with glioblastoma this year, next year or in the next decade. There are existing drugs that we can use, but the system provides little incentive to repurpose them for small patient populations, and there is little prestige in doing so. This is, at heart, a market failure. There are only two routes to more trials. One is the public and charitable route, which requires a real change in priorities and funding, and a pivot towards trying repurposed drugs. The other is the private sector, which will not deliver for rare cancers without intervention. If we want commercial trials for rare cancers, we must be honest about the tools available to us. Either we require pharmaceutical companies to test major cancer drugs on rare cancers, or we incentivise them to do so. There is no third way—and that is painful for a Blairite like me to say. I hope that the national cancer plan will signal real change. Without our Secretary of State for Health and Social Care, and without the cancer Minister, my hon. Friend the Member for West Lancashire (Ashley Dalton), there would be no rare cancer chapter in the national plan. However, if the current system carries on, we will be having this debate forever, without progress, and our loved ones will continue to die in shocking circumstances. That is why this debate matters, and why a shake-up is not radical, but long overdue.